 | • レポートコード：MRC23Q36299 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の原発性硬化性胆管炎（PSC）市場について調査・分析し、世界の原発性硬化性胆管炎（PSC）市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（医療、肝移植、その他）、用途別セグメント分析（病院、クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Acorda Therapeutics、Gilead Sciences、NGM Biopharmaceuticals、Intercept Pharmaceuticals、Dr. Falk Pharma、Allergan、Shire、Durect Corporation、Conatus Pharmaceuticals、Sirnaomics、Shenzhen HighTide Biopharmaceutical、Glenmark、Impax Laboratories、Mylan、Teva Pharmaceuticals、Daewoong Pharmaceutical、Mitsubishi Tanabe Pharma、Lannettなどが含まれています。世界の原発性硬化性胆管炎（PSC）市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、原発性硬化性胆管炎（PSC）市場規模を推定する際に考慮しました。本レポートは、原発性硬化性胆管炎（PSC）の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、原発性硬化性胆管炎（PSC）に関するビジネス上の意思決定に役立てることを目的としています。 ・原発性硬化性胆管炎（PSC）市場の概要 - 原発性硬化性胆管炎（PSC）のタイプ別セグメント - 世界の原発性硬化性胆管炎（PSC）市場規模：タイプ別分析（医療、肝移植、その他） - 原発性硬化性胆管炎（PSC）の用途別セグメント - 世界の原発性硬化性胆管炎（PSC）市場規模：用途別分析（病院、クリニック、その他） - 世界の原発性硬化性胆管炎（PSC）市場規模予測（2018年-2029年） ・原発性硬化性胆管炎（PSC）市場の成長トレンド - 原発性硬化性胆管炎（PSC）の地域別市場規模（2018年-2029年） - 原発性硬化性胆管炎（PSC）市場ダイナミクス - 原発性硬化性胆管炎（PSC）の業界動向 - 原発性硬化性胆管炎（PSC）市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：医療、肝移植、その他 - 世界の原発性硬化性胆管炎（PSC）のタイプ別市場規模（2018年-2023年） - 世界の原発性硬化性胆管炎（PSC）のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、クリニック、その他 - 世界の原発性硬化性胆管炎（PSC）の用途別市場規模（2018年-2023年） - 世界の原発性硬化性胆管炎（PSC）の用途別市場規模（2024年-2029年） ・原発性硬化性胆管炎（PSC）の地域別市場規模 - 北米の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - アメリカの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - ヨーロッパの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - アジア太平洋の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - 中国の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - 日本の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - 韓国の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - インドの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - オーストラリアの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - 中南米の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） - 中東・アフリカの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Acorda Therapeutics、Gilead Sciences、NGM Biopharmaceuticals、Intercept Pharmaceuticals、Dr. Falk Pharma、Allergan、Shire、Durect Corporation、Conatus Pharmaceuticals、Sirnaomics、Shenzhen HighTide Biopharmaceutical、Glenmark、Impax Laboratories、Mylan、Teva Pharmaceuticals、Daewoong Pharmaceutical、Mitsubishi Tanabe Pharma、Lannett ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Primary Sclerosing Cholangitis (PSC) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Primary Sclerosing Cholangitis (PSC) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Primary Sclerosing Cholangitis (PSC) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Primary Sclerosing Cholangitis (PSC) in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Primary Sclerosing Cholangitis (PSC) include Acorda Therapeutics, Gilead Sciences, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr. Falk Pharma, Allergan, Shire, Durect Corporation and Conatus Pharmaceuticals, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Sclerosing Cholangitis (PSC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Sclerosing Cholangitis (PSC).
The Primary Sclerosing Cholangitis (PSC) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Primary Sclerosing Cholangitis (PSC) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Sclerosing Cholangitis (PSC) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan
Shire
Durect Corporation
Conatus Pharmaceuticals
Sirnaomics
Shenzhen HighTide Biopharmaceutical
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Segment by Type
Medical Treatement
Liver Transplantation
Others
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Primary Sclerosing Cholangitis (PSC) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Medical Treatement
1.2.3 Liver Transplantation
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis (PSC) Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis (PSC) Market Perspective (2018-2029)
2.2 Primary Sclerosing Cholangitis (PSC) Growth Trends by Region
2.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Primary Sclerosing Cholangitis (PSC) Historic Market Size by Region (2018-2023)
2.2.3 Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Region (2024-2029)
2.3 Primary Sclerosing Cholangitis (PSC) Market Dynamics
2.3.1 Primary Sclerosing Cholangitis (PSC) Industry Trends
2.3.2 Primary Sclerosing Cholangitis (PSC) Market Drivers
2.3.3 Primary Sclerosing Cholangitis (PSC) Market Challenges
2.3.4 Primary Sclerosing Cholangitis (PSC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue (2018-2023)
3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Players (2018-2023)
3.2 Global Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis (PSC) Revenue
3.4 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis (PSC) Revenue in 2022
3.5 Primary Sclerosing Cholangitis (PSC) Key Players Head office and Area Served
3.6 Key Players Primary Sclerosing Cholangitis (PSC) Product Solution and Service
3.7 Date of Enter into Primary Sclerosing Cholangitis (PSC) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Type (2018-2023)
4.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Type (2024-2029)
5 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Application (2018-2023)
5.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
6.2 North America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
6.4 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
7.4 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
8.2 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023)
8.4 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
9.2 Latin America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
9.4 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
10.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
10.4 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics Company Detail
11.1.2 Acorda Therapeutics Business Overview
11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Introduction
11.1.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.1.5 Acorda Therapeutics Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Introduction
11.2.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals Company Detail
11.3.2 NGM Biopharmaceuticals Business Overview
11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.3.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.3.5 NGM Biopharmaceuticals Recent Development
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals Company Detail
11.4.2 Intercept Pharmaceuticals Business Overview
11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.4.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.4.5 Intercept Pharmaceuticals Recent Development
11.5 Dr. Falk Pharma
11.5.1 Dr. Falk Pharma Company Detail
11.5.2 Dr. Falk Pharma Business Overview
11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.5.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.5.5 Dr. Falk Pharma Recent Development
11.6 Allergan
11.6.1 Allergan Company Detail
11.6.2 Allergan Business Overview
11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Introduction
11.6.4 Allergan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.6.5 Allergan Recent Development
11.7 Shire
11.7.1 Shire Company Detail
11.7.2 Shire Business Overview
11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Introduction
11.7.4 Shire Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.7.5 Shire Recent Development
11.8 Durect Corporation
11.8.1 Durect Corporation Company Detail
11.8.2 Durect Corporation Business Overview
11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Introduction
11.8.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.8.5 Durect Corporation Recent Development
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals Company Detail
11.9.2 Conatus Pharmaceuticals Business Overview
11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.9.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.9.5 Conatus Pharmaceuticals Recent Development
11.10 Sirnaomics
11.10.1 Sirnaomics Company Detail
11.10.2 Sirnaomics Business Overview
11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Introduction
11.10.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.10.5 Sirnaomics Recent Development
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical Company Detail
11.11.2 Shenzhen HighTide Biopharmaceutical Business Overview
11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.11.4 Shenzhen HighTide Biopharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.11.5 Shenzhen HighTide Biopharmaceutical Recent Development
11.12 Glenmark
11.12.1 Glenmark Company Detail
11.12.2 Glenmark Business Overview
11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Introduction
11.12.4 Glenmark Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.12.5 Glenmark Recent Development
11.13 Impax Laboratories
11.13.1 Impax Laboratories Company Detail
11.13.2 Impax Laboratories Business Overview
11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Introduction
11.13.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.13.5 Impax Laboratories Recent Development
11.14 Mylan
11.14.1 Mylan Company Detail
11.14.2 Mylan Business Overview
11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Introduction
11.14.4 Mylan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.14.5 Mylan Recent Development
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Detail
11.15.2 Teva Pharmaceuticals Business Overview
11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.15.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.15.5 Teva Pharmaceuticals Recent Development
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Company Detail
11.16.2 Daewoong Pharmaceutical Business Overview
11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.16.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.16.5 Daewoong Pharmaceutical Recent Development
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma Company Detail
11.17.2 Mitsubishi Tanabe Pharma Business Overview
11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.17.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.17.5 Mitsubishi Tanabe Pharma Recent Development
11.18 Lannett
11.18.1 Lannett Company Detail
11.18.2 Lannett Business Overview
11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Introduction
11.18.4 Lannett Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.18.5 Lannett Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details